生命科学资讯
生物技术与制药领域的最新动态
10x Genomics (TXG) Reports Earnings Tomorrow: What To Expect - The Chronicle-Journal
Gilead dips as ‘strong’ earnings outweighed by high expectations for new HIV drug
Simplifying library prep: All in a day’s work for Louise Fraser - Illumina
Moderna指控FDA改变标准，拒绝审查其流感疫苗。
Moderna accuses FDA of shifting standard as agency refuses flu shot review
同构科技宣布其新型AI药物设计引擎取得重大突破。
Isomorphic claims major advance with new AI drug design engine
ILiAD融资1.15亿美元推进百日咳疫苗研发。
ILiAD raises $115M round to advance whooping cough vaccine
艾伯维与阿斯利康在路易斯安那州340B合同药店争议中上诉失败。
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
美国国立卫生研究院因安全问题叫停大型中风研究中的低剂量拜瑞妥试验组。
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
Nektar持续复苏，湿疹药物在后续研究中效果稳定。
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
2026年2月10日融资动态
Financings for Feb. 10, 2026
2026年2月10日门诊
In the clinic for Feb. 10, 2026
2026年2月10日其他值得关注新闻
Other news to note for Feb. 10, 2026
2026年2月10日监管动态
Regulatory actions for Feb. 10, 2026
制药公司及高管被控证券欺诈
Pharma company, execs charged with securities fraud
阿斯利康能否实现800亿美元营收目标？
Is AstraZeneca on track to meet its $80B revenue target?
FDA再次拒绝再生元生物治疗，基因疗法再受打击。
FDA rejects Regenxbio treatment in another blow to gene therapy
沃特世公司（WAT）：古根海姆重申“买入”评级——GuruFocus
Waters Corporation (WAT): Guggenheim Reiterates 'Buy' Rating wit - GuruFocus
诺和与希姆斯之争的余波
The fallout from Novo vs. Hims
行星微生物组结构及跨异质生境的全能驱动基因流
Planetary microbiome structure and generalist-driven gene flow across disparate habitats